Open AccessThe antidepressant effect and safety of non-intranasal esketamine: A systematic review
Author(s) -
Sanne Y Smith-Apeldoorn,
Maurice Vischjager,
Jolien K E Veraart,
Jeanine Kamphuis,
Marije aan het Rot,
Robert A. Schoevers
Publication year - 2022
Publication title -
journal of psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.333
H-Index - 114
eISSN - 1461-7285
pISSN - 0269-8811
DOI - 10.1177/02698811221084055
Subject(s) - treatment resistant depression , medicine , ketamine , depression (economics) , anesthesia , psychotomimetic , randomized controlled trial , major depressive disorder , antidepressant , nmda receptor , receptor , amygdala , hippocampus , economics , macroeconomics
The introduction of esketamine into the field of psychiatry comes on the heels of excitement from studies on racemic ketamine. While the intranasal route has been the most studied to date, other modes of administration of esketamine may also be of interest in the management of depression.